• Oral Disorders Linked to SARS-CoV-2, Statin Use Increases Survival Rate, Abnormal Sodium Levels Predict Death Risk: COVID-19 Updates

    Mar 05 | Clinical Research News I Repurposed arthritis drug falls short in Phase 3 clinical trial, optimal timing for donating convalescent plasma is within 60 days of symptom onset, most pregnant women and mothers report that they will vaccinate themselves and children, and only small percentage of COVID-19 patients suffer stroke, risk increases with age and CV risk factors. Plus: Clinicians warn of delayed injection-site reaction to Moderna vaccine for proper management and swollen salivary glands may be a common COVID-19 side effect. More
  • SCOPE 2021: New Players in Clinical Trials, AstraZeneca on RWE, Transcelerate Updates

    Mar 04 | Clinical Research News | Day two of the Summit for Clinical Ops Executives (SCOPE) brings more updates from big pharma on the impacts of the COVID-19 pandemic, how AstraZeneca in deploying real-world evidence (RWE) in trials across broad therapeutic areas, and more. More
  • Medidata Named Winner of 2021 Participant Engagement Award

    Mar 03 | Clinical Research News | Live at SCOPE yesterday, the winner of the 2021 Participant Engagement Award was chosen by a panel of judges. Patient Centricity by Design, a project from Medidata, was named the grand prize winner. More
  • SCOPE 2021: Pfizer, GSK’s Approach to COVID-19 Research, Patient Voice In Trials

    Mar 03 | Clinical Research News | At the kickoff day for the Summit for Clinical Ops Executives 2021, teams from Pfizer talk vaccine development, Bayer, Pfizer, Abbvie and GSK report on the role of the patient in trial development, and GSK discusses the need for a “single source of truth” in pandemic response. More
  • Pandemic Highlights Value Of Remote Clinical Trials, Drug Repurposing

    Mar 02 | Clinical Research News | A keynote address earlier this morning during opening ceremonies of the 2021 Summit for Clinical Ops Executives (SCOPE) offers glimmers of hope that the notoriously rigid clinical trial process may retain at least a few of the warp-speed changes introduced by the COVID-19 pandemic. More
  • Intranasal Vaccines, Vax Data for RWD Exploration, Down Syndrome Impacts: COVID-19 Updates

    Feb 26 | Clinical Research News | A survey of how rehabilitation is helping patients with severe COVID-19, what COVID-19 means for Down Syndrome patients, and the timing of vaccines. Plus: real world data for COVID-19 vaccination, intranasal COVID-19 vaccine, more. More
  • It Took A Village To Speed Pfizer COVID-19 Vaccine Into Arms

    Feb 25 | Clinical Research News | Deployment of clinical trials for Pfizer’s COVID-19 vaccine candidate was the fastest in the company’s history, and possibly industry-wide. Six weeks after the decision was made to run the combined phase 1/2/3 study, the first patient was enrolled and, six months later, it had all the safety and efficacy data needed to request Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to start getting the vaccine into people’s arms. More
  • Adaptive Trial Design Takes Center Stage During Pandemic

    Feb 23 | Clinical Research News | The pandemic has had some “silver linings” for clinical studies and the overall U.S. healthcare system, according to speakers discussing adaptive trial design at the recent COVID-19 and Cancer virtual meeting of the American Association for Cancer Research (AACR). We can’t go back to business as usual. More
  • PTSD, Lasting Heart Damage, Brain Findings: Lasting Impacts for COVID-19 Patients

    Feb 19 | Clinical Research News | Europe’s vaccination priority for the mentally ill, fighting “vaccine nationalism”, how the humidity inside the face mask can help. Plus: trials of remdesivir in pregnant women, EMA releases guidance on trials during pandemic, and seeking priority vaccines for cancer patients, diabetes sufferers. More
  • GSK’s Protocol Design Lab Offers Actionable Insights To Study Teams

    Feb 18 | Clinical Research News | A Protocol Design Lab (PDL) launched by GlaxoSmithKline (GSK) at the end of 2019 is endeavoring to harness insights from real-world data, clinical trials, and patients themselves to create “operationally viable” protocols linked to predetermined value drivers—notably, clinical studies that are faster and less costly to conduct and include a greater diversity of patients. More
View more articles

DIA NOW is the source for life science knowledge. Comprehensive and customizable, and backed by DIA's extensive history, global reach, and experience, you'll stay on top of trends and receive up-to-the-minute updates on a wide variety of critical issues in the life sciences arena. Get your one-month free trial today!